TransMolecular, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TransMolecular, Inc.
Obituary: Ranjit Shahani, Ex-Novartis India Chief Who ‘Traveled Light’
Industry veteran and mentor to many, Ranjit Shahani steered Novartis India with seeming calm through a rocky phase when the Glivec patent case ruling didn't go the Swiss multinational's way - perhaps not unusual for someone who had seen the ebbs and flows of life closely when his parents moved to India as refugees from Pakistan.
Trends Shaping India Pharma: Next-Gen Therapies, Adjacencies, LOE Strategies And More
The arrival of an indigenous CAR-T cell therapy, a shot at GLP-1s and Parkinson’s disease, strides into adjacencies and an “easy revenue stream” formula for products set to lose exclusivity are some of the striking developments seen playing out in India. Industry leaders, including Cipla’s CEO, share their views with Scrip on some of the key trends in the first instalment of this two-part roundup.
J.P. Morgan: Serial Acquirer JB Chemicals Talks Strategy, Making ‘Big Brands Bigger’
Private equity-controlled J B Chemicals and Pharmaceuticals, which recently snapped up a basket of ophthalmology brands from Novartis in India, expects to drive momentum to make key product franchises bigger and stronger, while also building on the CDMO business.
Arena BioWorks Wants To Address Inefficiency Of Early R&D Finance
Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice